scispace - formally typeset
H

Hironori Ohde

Researcher at Osaka University

Publications -  15
Citations -  153

Hironori Ohde is an academic researcher from Osaka University. The author has contributed to research in topics: Plasma renin activity & Renin–angiotensin system. The author has an hindex of 9, co-authored 15 publications receiving 152 citations.

Papers
More filters
Journal ArticleDOI

Hormonal responses to long‐term converting enzyme inhibition in hypertensive patients

TL;DR: It is concluded that another mechanism, such as enhancement of renal or local kinin‐prostaglandin system, as well as suppression of the renin‐angiotensin‐aldosterone system may be involved in the long‐term efficacy of captopril.
Journal ArticleDOI

Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells.

TL;DR: The neuroprotective function of (-)-BPAP and the related compounds was examined against apoptosis induced by an endogenous neurotoxin, N-methyl( R)salsolinol [NM(R)Sal], a possible pathogenic toxin in Parkinson's disease, in human dopaminergic neuroblastoma SH-SY5Y cells.
Journal ArticleDOI

The Effect of Aging on Urinary Kallikrein Excretion in Normotensive Subjects and in Patients with Essential Hypertension

TL;DR: The age-related decrease of U(kal)V in normal subjects may be due to the reduced activity of the renin-angiotensin-aldosterone system, which is related to the pathogenesis or pathophysiology of essential hypertension.
Journal ArticleDOI

Responses of Active and Inactive Plasma Renin and Changes in Urinary Kallikrein and Plasma Prekallikrein to Various Conditions in Normal Subjects

TL;DR: The present data suggest that the mechanisms ofr the control of inactive and active renin are different, and neither renal nor plasma kallikrein seems to be consistently involved in the in vivo activation of inactive renin.
Patent

Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives

TL;DR: Novel 2-(N-cyanoimino)thiazolidin-4-one derivatives represented by general formula (I), which exhibit excellent cholesterollowering and triglyceride-lowering activities and are useful in the prevention or treatment of hyperlipidemia and diseases resulting therefrom.